All In Biotech

NDA 050821 · B Braun

Cefepime and Dextrose In Duplex Container

Cefepime Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

May 6, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

78

22 Phase 3, 8 recruiting

FAERS reports

1,805

1,700 serious, 459 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2026.

Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia ( 1.1 ) Empiric therapy for febrile neutropenic patients ( 1.2 ) Uncomplicated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for...

Mechanism: Cefepime is a cephalosporin antibacterial drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 6, 2010 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
2 products under this application
  • CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER · CEFEPIME HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
  • CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER · CEFEPIME HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefepime" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia192
  • pyrexia191
  • pneumonia138
  • acute kidney injury105
  • drug ineffective100
  • off label use87
  • platelet count decreased77
  • anaemia74
  • neutrophil count decreased73
  • neutropenia72
  • rash72
  • diarrhoea68

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20056
20068
20075
200814
200913
201024
201174
201268
201340
201433
201540
201642
201732
201865
201990
202093
2021144
2022218
2023264
2024230
2025182
2026114

Recalls

2 FDA enforcement reports for this application.

  • Nov 21, 2013 · Class I · Terminated

    Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.

  • Oct 15, 2013 · Class I · Terminated

    Presence of Particulate Matter: The 1g Cefepime for Injection USP and Dextrose Injection USP lot has been found to contain visible organic particulate matter in a reserve sample unit.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 276 on PubMed

Sponsor: B Braun

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.